News

BlockBeats News, March 27th, according to loris.tools data, following Trump's frequent weekend "raids" this year, Trade.xyz, focusing on US stock and commodity futures trading, took advantage of the trading demand during the traditional financial market's closing hours. Since January this year, Trade.xyz has seen a qualitative breakthrough in trading volume, hitting a single-day trading volume record of $5.31 billion on March 23rd. Although trading volume has shown a downward trend in the past two days, its market share in the HIP-3 overall market still exceeds 90%. In addition, the mobile trading platform Dreamcash in the HIP-3 ecosystem saw a daily trading volume of $159 million, ranking second after Trade.xyz.

1. The Indian federal government announced a reduction in diesel and petrol taxes to cushion refining companies from the surge in crude oil prices. According to the government announcement, the special excise duty on petrol has been cut from 13 rupees per liter to 3 rupees per liter, while the special excise duty on diesel has been reduced from 10 rupees per liter to zero.2. This move aims to provide support for refining companies, which have until now largely absorbed the increased costs caused by rising crude oil prices. Boosted by the news, shares of Hindustan Petroleum Corporation rose as much as 4%, and Bharat Petroleum Corporation saw gains of up to 4.9%, though most of these gains later narrowed.3. With the Strait of Hormuz essentially blocked, international oil prices remain high. As a major energy importer, India is facing imported inflationary pressure. These tax reductions are intended to ease domestic fuel price pressures and lessen the burden on refining companies.

This financing aims to provide funding support for the company's pipeline of autoimmune disease drugs under development, particularly for the clinical development of core projects such as obexelimab. According to the announcement, the issuance scale of the convertible notes is $175 million, with an annual interest rate of 2.50%, maturing in 2032. Under specific conditions, holders of the notes may convert them into ordinary shares of the company, with the initial conversion price set at a significant premium to the reference share price. The issuance size of ordinary shares is $125 million, with the issue price reflecting a certain discount to the recent share price. Both issuances were oversubscribed, demonstrating investors’ recognition of Zenas’ technology platform in the autoimmune field.Optimizing capital cost through financing structure The structure of this concurrent financing reflects the company’s balanced consideration between capital cost and equity dilution. The low coupon rate of the convertible notes helps reduce short-term interest expenses, while the conversion premium provides a degree of protection against equity dilution for existing shareholders. The issuance of ordinary shares directly bolsters the company's equity capital base. This hybrid financing model is quite common in the biotech industry, especially for companies like Zenas that are in the clinical phase and require significant R&D investment. Goldman Sachs and JPMorgan acted as joint bookrunners for this issuance.Industry commentators have pointed out that, against the backdrop of a relatively cautious biotech IPO market, Zenas’ ability to successfully complete large-scale concurrent financing reflects institutional investors’ confidence in its proprietary platform and drug pipeline. The company plans to use the net proceeds primarily to advance the global phase III clinical trials of obexelimab, as well as research into other early-stage autoimmune candidates.Intensified competition in the autoimmune disease track Zenas BioPharma focuses on developing innovative therapies targeting autoimmune diseases. Its leading product obexelimab is a bispecific antibody designed to simultaneously target CD19 and FcγRIIb on the surface of B cells, and is currently being clinically developed for multiple autoimmune indications. The global market for autoimmune disease drugs is vast and continues to grow, but competition is also intensifying—not only from blockbuster products of major pharmaceutical companies, but also from numerous innovative therapies in development by biotech firms.This financing will provide Zenas with sufficient capital runway to support the advancement of its key clinical trials. Successful clinical data will be a key catalyst for future value appreciation of the company. Analysts believe that if the clinical data of obexelimab is positive, Zenas is poised to become an important player in the autoimmune field, and may even attract interest from large pharmaceutical companies for acquisitions. However, drug development itself carries high risks, and investors must continue to pay attention to subsequent clinical progress and industry developments.